Vicore Pharma Holding AB

NASDAQ:VCRE

Medical - Pharmaceuticals

Healthcare
$9.90 -1.66%

-$0.24 today

Market cap
$279.65M
Beta
0.15

Volume 0.00M

Average 0.26M

VCRE Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Vicore Pharma Holding ABNASDAQ: VCRE

Net Change in Cash · Q2 FY2026 · quarter ended Jun 2026

Net change in cash turns positive

Q2 FY2026 net change in cash was SEK 4.34M, compared with -SEK 363.87M a year earlier. Trailing-twelve-month net change in cash was -SEK 75.53M. Over 3 fiscal years it compounded at +149.1% a year.

Context

  • Net change in cash amounted to 15139.0% of revenue in FY2025, up 14386.9 pp from a year earlier.
  • Net change in cash increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly net change in cash holds near SEK 4.34M or moves back toward the trailing-twelve-month quarterly average of -SEK 18.88M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
SEK 4.34M+102.2% QoQ
Last fiscal yearDec 2025
-SEK 577.85M-170.3% YoY
LTMJun 2026
-SEK 75.53M-1039.4% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+101.2%——
1 year-170.3%——
3-year CAGR+149.1%——
5-year CAGR——
10-year CAGR——

Net Change in Cash history

SEK · from the cash flow

Latest · FY2025
(577.85M) SEK
Year-over-year change
-170.3%

Net Change in Cash vs competitors

How VCRE compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -1039.4% is the lowest of 2, against a peer median of +119.8%.
  • Net change in cash amounts to 5679.1% of revenue for VCRE, versus a peer median of 21.4%.
VCRE Competitors
Net Change in Cash for VCRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LQDALiquidia CorporationLTM Jun 2026$96.36M USD+119.8%-26.5%21.4%
VCREVicore Pharma Holding ABLTM Jun 2026SEK 75.53M SEK-1039.4%+149.1%5679.1%
AVLNAvalyn Pharma Inc. Common Stock—— ———
Peer median (excluding VCRE) —+119.8%-26.5%21.4%

Competitors are the stored peer set for VCRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

SEK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(32.78M)(290.73M)(321.51M)(194.19M)(452.39M)
Depreciation & Amortization397.75K3.61M3.42M2.24M0
Deferred Income Tax00000
Stock-Based Compensation(172.79K)0000
Change in Working Capital(37.59K)(20.94M)(10.65M)(1.84M)40.81M
Accounts Receivables(37.59K)(1.6M)(4.28M)(35.6M)(3.08M)
Inventory00000
Accounts Payables00000
Other Working Capital0(19.34M)(6.36M)33.77M43.89M
Other Non-Cash Items(231.23M)8.13M79.15M28.84M35.84M
Operating Cash Flow(263.82M)(299.92M)(249.58M)(164.95M)(375.74M)
Capital Expenditures0(3M)000
Acquisitions (Net)00000
Purchases of Investments(76.61M)0(199.04M)(64.81M)(983.95M)
Sales of Investments69.64M77M54.58M213.85M383.45M
Other Investing Activities00000
Investing Cash Flow(6.96M)74M(144.46M)149.04M(600.51M)
Debt Repayment00000
Common Stock Issued316.8M200M500.41M882.14M455.1M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(237.78K)(12.96M)(29.55M)(48.08M)(24.55M)
Financing Cash Flow316.56M187.04M470.86M834.06M430.54M
Effect of Forex Changes(26.64M)1.48M04.23M(32.16M)
Net Change in Cash2.3M(37.4M)76.82M822.38M(577.85M)
Free Cash Flow(263.82M)(302.92M)(249.58M)(164.95M)(375.74M)

Vicore Pharma Holding AB

NASDAQ:VCRE

Intrinsic Alpha fair value

Locked

Current Price

$9.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.